Rigel Pharmaceuticals RIGL Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue recognized by Product | ||||||
| Delivery of drug supplies, royalties and others | $3.9M-42.6% | $4.12M-41.8% | $5.4M-15.4% | $2.76M-18.7% | $6.78M+92.1% | |
| Development Milestones | $0-100% | —— | —— | —— | $3M— | |
| Discounts and allowances | -$20.47M-23.0% | -$19.04M+3.2% | -$21.56M-23.9% | -$20.74M-33.6% | -$16.64M-34.0% | |
| Gross product sales | $75.39M+25.2% | $84.45M+27.6% | $85.62M+52.0% | $79.69M+62.7% | $60.19M+56.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Rigel Pharmaceuticals break its business down?
- Rigel Pharmaceuticals (RIGL) reports revenue recognized by product across 4 parts — Delivery of drug supplies, royalties and others, Development Milestones, Discounts and allowances and Gross product sales. Each is extracted from the segment footnotes and tracked over time.
- Where does Rigel Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Rigel Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
